1 The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China 2 Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China A 42 year-old ...

These runs all were done with the multimer version 2 model of Alphafold 2 in single sequence mode (i.e. no MSA was used) as a negative control, to highlight the importance of a quality MSA. The left ...

Each FASTA file contains the entire sequence of the subject scFv, a colon “:”, and then the candidate linear epitope which represents a small section of the target antigen protein that changes ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Bullous Pemphigoid. According to GlobalData, Phase III drugs for Bullous Pemphigoid does not have ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

Recombinant phages that can specifically bind cytokines were constructed by inserting a nanobody sequence (the produced scFv was not thoroughly examined; however, further research is needed for ...